10-Q: Black Diamond Therapeutics Q1 2026 Earnings Report

Black Diamond Therapeutics reports a net loss of $9.0 million for Q1 2026, with cash reserves projected to fund operations into the second half of 2028.

Summary

• Black Diamond Therapeutics reported a net loss of $9.0 million for the first quarter ended March 31, 2026, compared to a net income of $56.5 million in the same period of 2025.
• Total operating expenses decreased to $11.3 million from $15.5 million in the prior year quarter, driven by reduced research and development and general administrative costs.
• The company's cash, cash equivalents, and investments stood at $118.3 million as of March 31, 2026, which is expected to fund operations into the second half of 2028.
• Research and development expenses decreased by $3.5 million year-over-year, primarily due to the deprioritization of BDTX-4933 and progression in the silevertinib NSCLC trial, partially offset by increased spending on the silevertinib GBM trial.
• The company continues to advance its lead clinical-stage program, silevertinib, with a Phase 2 trial in NSCLC and a newly initiated randomized Phase 2 trial in EGFRvIII+ glioblastoma (GBM).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net loss, absence of recurring revenue, and the substantial need for future capital, despite positive clinical trial data and a manageable cash runway.

Positives

• Cash reserves of $118.3 million are projected to fund operations into the second half of 2028, providing a significant runway.
• Operating expenses decreased by $4.2 million year-over-year, indicating improved cost management.
• Research and development expenses decreased, with specific reductions attributed to the licensing of BDTX-4933 and efficiencies in the silevertinib NSCLC program.
• Silevertinib demonstrated encouraging CNS activity in NSCLC patients, with an 86% CNS Objective Response Rate (ORR) in a Phase 2 trial.
• The company initiated a randomized Phase 2 trial for silevertinib in newly diagnosed EGFRvIII+ glioblastoma (GBM) patients in May 2026.

Negatives

• Reported a net loss of $9.0 million for the quarter, a significant shift from the $56.5 million net income in Q1 2025.
• License revenue dropped to $0 in Q1 2026 from $70.0 million in Q1 2025, due to the upfront payment from Servier in the prior year.
• The company has a substantial accumulated deficit of $473.8 million as of March 31, 2026.
• The company will require substantial additional funding to support ongoing operations and growth strategies, with no guarantee of obtaining it on acceptable terms.

Risks

• The company has recurring losses and negative cash flows from operations and expects to continue generating operating losses for the foreseeable future.
• There is no assurance that the company's research and development will be successfully completed, that adequate protection for its technology will be obtained, or that any products developed will obtain necessary government regulatory approval or be commercially viable.
• The company is dependent on the services of its employees, consultants, and service providers.
• The company may not be able to obtain additional funding on acceptable terms, or at all, which could force it to delay, reduce, or eliminate research and development programs.
• Macroeconomic and geopolitical developments, including inflation, interest rate fluctuations, and global conflicts, could adversely affect the company's business, research and development efforts, and ability to access capital markets.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future and requires substantial additional funding. Its current cash, cash equivalents, and investments are expected to fund operations into the second half of 2028. Future funding will be sought through equity offerings, debt financings, collaborations, and strategic alliances.

Management Comments

• We believe that our clinical-stage lead product candidate, silevertinib, has the potential to treat newly diagnosed patients with EGFRm NSCLC, as well as those with recurrent disease, based upon silevertinibs ability to address greater than 50 classical and non-classical oncogenic driver mutations with greater potency than other EGFR tyrosine kinase inhibitors (TKIs), as well as uniquely target the C797S resistance mutation which can be acquired after treatment with osimertinib.
• Based on these data and together with the robust CNS ORR demonstrated by silevertinib to date in our Phase 2 trial in frontline EGFRm NSCLC patents, we believe that silevertinib is uniquely positioned as a potential treatment for patients with newly diagnosed EGFR-altered GBM.
• We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028.
• We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates.

Industry Context

StockSavvy.ai notes that Black Diamond Therapeutics operates in the highly competitive and capital-intensive oncology drug development sector. The company's focus on MasterKey therapies targeting families of oncogenic mutations aligns with industry trends towards precision medicine. The licensing of BDTX-4933 to Servier is a common strategy for clinical-stage biotech companies to advance pipeline assets while conserving resources and potentially generating non-dilutive revenue.

Comparison to Industry Standards

• The Objective Response Rate (ORR) of 60% for silevertinib in frontline NSCLC patients with non-classical EGFR mutations, and a CNS ORR of 86%, appears strong compared to historical benchmarks for similar patient populations, though direct comparisons require careful consideration of trial design and patient characteristics.
• The company's cash runway extending into the second half of 2028 is a positive indicator, as many clinical-stage biotechs face funding challenges sooner.
• The net loss of $9.0 million for the quarter is typical for clinical-stage biotechnology companies investing heavily in R&D, but the significant decrease in revenue compared to the prior year's upfront payment highlights the lumpy nature of such income.

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Other investors in Revelio Therapeutics, Inc. include Versant Ventures and New Enterprise Associates (NEA), who are also shareholders of Black Diamond Therapeutics.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may face uncertainty regarding future funding and potential reductions in R&D programs if capital is not secured.
• Creditors and suppliers may face risks if the company is unable to secure sufficient funding to meet its obligations.

Next Steps

• Present updated results from the Phase 2 NSCLC trial, including preliminary duration of response (DOR) and progression-free survival (PFS) data, at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 - June 2, 2026.
• Continue advancing the randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ glioblastoma (GBM) patients, with the first patient dosed in May 2026.
• Explore potential partnership opportunities to advance silevertinib into pivotal development.
• Seek additional capital through private or public equity financings, debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements.

Key Dates

Recommendation

The company shows promising clinical data for silevertinib, particularly in CNS activity, and has a sufficient cash runway into late 2028. However, the significant net loss, lack of recurring revenue, and the substantial need for future capital raises introduce considerable risk. A 'hold' recommendation reflects the balance between potential upside from clinical progress and the financial uncertainties.

Keywords

Black Diamond Therapeutics, BDTX, Form 10-Q, Quarterly Report, Oncology, Silevertinib, EGFR, NSCLC, Glioblastoma, Biotechnology, Clinical Trials, SEC Filing